These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37838305)

  • 1. The effects of switching from ceftriaxone to cefotaxime on the occurrence of third-generation cephalosporin-resistant Enterobacterales: A stepped-wedge cluster randomized trial.
    Bouiller K; Gbaguidi-Haore H; Hocquet D; Crépin T; Wendling D; Borot S; Chirouze C; Bertrand X
    Infect Dis Now; 2024 Feb; 54(1):104806. PubMed ID: 37838305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study.
    Aiken AM; Rehman AM; de Kraker MEA; Madrid L; Kebede M; Labi AK; Obeng-Nkrumah N; Nyamwaya B; Kagucia E; Cocker D; Kawaza K; Lester R; Iregbu KC; Medugu N; Nwajiobi-Princewill PI; Dramowski A; Sonda T; Hemed A; Fwoloshi S; Ojok D; Scott JAG; Whitelaw A;
    Lancet Infect Dis; 2023 Nov; 23(11):1280-1290. PubMed ID: 37454672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study.
    Pilmis B; Jiang O; Mizrahi A; Nguyen Van JC; Lourtet-Hascoët J; Voisin O; Le Lorc'h E; Hubert S; Ménage E; Azria P; Borie MF; Mahé A; Mourad JJ; Trabattoni E; Ganansia O; Zahar JR; Le Monnier A
    Int J Infect Dis; 2021 Mar; 104():617-623. PubMed ID: 33453395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
    Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
    Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, comparative study of cefotaxime and ceftriaxone for treatment of uncomplicated gonorrhea.
    McCormack WM; Mogabgab WJ; Jones RB; Hook EW; Wendel GD; Handsfield HH
    Sex Transm Dis; 1993; 20(5):269-73. PubMed ID: 8235924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
    Kim BN; Woo JH; Kim YS; Ryu J; Kim MN; Pai CH
    Chemotherapy; 2000; 46(5):303-8. PubMed ID: 10965094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children.
    Goldwater PN
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2150-2. PubMed ID: 8540735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.
    Burdet C; Grall N; Linard M; Bridier-Nahmias A; Benhayoun M; Bourabha K; Magnan M; Clermont O; d'Humières C; Tenaillon O; Denamur E; Massias L; Tubiana S; Alavoine L; Andremont A; Mentré F; Duval X;
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of cefotaxime and ceftriaxone in patients with uncomplicated gonorrhea.
    Jones RB; Mogabgab WJ; McCormack WM; Wendel GD
    Clin Ther; 1991; 13(5):550-6. PubMed ID: 1799912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes and Practices of the Use of Third-Generation Cephalosporins among Medical Doctors Practicing in Cameroon.
    Menkem EZ; Labo Nanfah A; Takang T; Ryan Awah L; Awah Achua K; Ekane Akume S; Fekam Boyom F
    Int J Clin Pract; 2023; 2023():8074413. PubMed ID: 36846498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attributable mortality and excess length of stay associated with third-generation cephalosporin-resistant Enterobacterales bloodstream infections: a prospective cohort study in Suva, Fiji.
    Loftus MJ; Young-Sharma TEMW; Lee SJ; Wati S; Badoordeen GZ; Blakeway LV; Byers SMH; Cheng AC; Cooper BS; Cottingham H; Jenney AWJ; Hawkey J; Macesic N; Naidu R; Prasad A; Prasad V; Tudravu L; Vakatawa T; van Gorp E; Wisniewski JA; Rafai E; Peleg AY; Stewardson AJ
    J Glob Antimicrob Resist; 2022 Sep; 30():286-293. PubMed ID: 35738385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniae.
    Barry AL; Fuchs PC
    J Clin Microbiol; 1996 Oct; 34(10):2609-12. PubMed ID: 8880533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis.
    Olivier C; Cohen R; Begué P; Floret D
    Pediatr Infect Dis J; 2000 Oct; 19(10):1015-7. PubMed ID: 11055609
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized study of cefotaxime versus ceftriaxone for uncomplicated gonorrhea.
    Mogabgab WJ; Lutz FB
    South Med J; 1994 Apr; 87(4):461-4. PubMed ID: 8153771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted screening for third-generation cephalosporin-resistant Enterobacteriaceae carriage among patients admitted to intensive care units: a quasi-experimental study.
    Dananché C; Bénet T; Allaouchiche B; Hernu R; Argaud L; Dauwalder O; Vandenesch F; Vanhems P
    Crit Care; 2015 Feb; 19(1):38. PubMed ID: 25879192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ceftriaxone with cefotaxime in serious chest infections.
    Reeves JH; Russell GM; Cade JF; McDonald M
    Chest; 1989 Dec; 96(6):1292-7. PubMed ID: 2684552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
    Adu A; Armour CL
    Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae.
    Muller A; Lopez-Lozano JM; Bertrand X; Talon D
    J Antimicrob Chemother; 2004 Jul; 54(1):173-7. PubMed ID: 15150164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
    Pallares R; Liñares J; Vadillo M; Cabellos C; Manresa F; Viladrich PF; Martin R; Gudiol F
    N Engl J Med; 1995 Aug; 333(8):474-80. PubMed ID: 7623879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.